References
- McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779.
- Leblanc S, Roux J, Tillaut H, et al. Disease-modifying therapy usage in patients with multiple sclerosis in France: a 6-year population-based study. Rev Neurol (Paris). 2021;177(10):1250–1261.
- Vermersch P, Suchet L, Colamarino R, et al. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017. Mult Scler Relat Disord. 2020;46:102521.
- Moisset X, Fouchard AA, Pereira B, et al. Untreated patients with multiple sclerosis: a study of French expert centers. Eur J Neurol. 2021;28(6):2026–2036.
- Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev. Epidemiol. Sante Publique. 2010;58(4):286–290.
- Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19(3):256–265.
- Moulis G, Lapeyre-Mestre M, Palmaro A, et al. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36(6):411–417.
- Palmaro A, Moulis G, Despas F, et al. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 2016 Dec;30(6):616–624.
- Foulon S, Maura G, Dalichampt M, et al. Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. J Neurol. 2017;264(6):1185–1192.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
- Box GE, Jenkins GM, Reinsel GC, et al. Time series analysis: forecasting and control. 5th edn. Hoboken: John Wiley and Sons; 2015.
- Hyndman RJ, Athanasopoulos G. Forecasting: principles and practice. 2nd (Melbourne, Australia.: OTexts); 2018. OTexts.com/fpp2
- Core Team R. R: a language and environment for statistical computing. Vienna Austria: R Foundation for Statistical Computing; 2019 [ URL https://www.R-projet.org/].
- Roux J, Guilleux A, Lefort M, et al. Use of healthcare services by patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data. Multiple Scler J Exp Trans Clin. 2019;5(4):2055217319896090.
- Ng HS, Zhu F, Kingwell E, et al. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Rev Neurother. 2021;21(1):131–140.
- Ha-Vinh P, Nauleau S, Clementz M, et al. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: evolution from 2013 to 2015 and demographic characteristics. Presse Med. 2019;48(1 Pt 1):e1–19.
- Koch-Henriksen N, Laursen B, Stenager E, et al. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry. 2017;88(8):626–631.
- Livingston T, Fay M, Iyer R, et al. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs. J Manag Care Spec Pharm. 2016;22(12):1385–1391.
- Jokubaitis VG, Spelman T, Lechner-Scott J, et al. The Australian multiple sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PloS One. 2013;8(3):e59694.
- Debouverie M, Laforest L, Van Ganse E, et al. Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients Mult Scler. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;15(2):251–257.
- Wong B, Cahill J, Rizvi S. Moving Towards a Cure for MS: increased immunosuppression and striving for No Evidence of Disease Activity (NEDA). R I Med J (2013). 2018.;101(2):26–29.